share_log

Altamira Therapeutics | 20-F/A: FY2023 Annual Report

Altamira Therapeutics | 20-F/A: FY2023 Annual Report

Altamira Therapeutics | 20-F/A：2023財年年報
美股SEC公告 ·  2024/07/01 19:13

Moomoo AI 已提取核心訊息

Altamira Medica AG reported financial results for its Bentrio nasal spray business for the fiscal year 2023. The company generated revenue of CHF 158,213 from product sales, primarily to distributors, while incurring a net loss of CHF 1.78 million. Cost of sales amounted to CHF 225,889, including inventory write-downs of CHF 54,393.Research and development expenses totaled CHF 1.43 million, mainly for completing the clinical trial of Bentrio in seasonal allergic rhinitis in Australia. The company received CHF 134,075 in R&D tax incentives from the Australian government. Selling, general and administrative expenses were CHF 372,479, including costs charged by related party Auris Medical AG.As of December 31, 2023, Altamira had cash and cash equivalents of CHF 490,388 and inventories of CHF 331,061. The company recognized deferred income of CHF 932,200 from an upfront payment related to its licensing agreement with Nuance Pharma for Bentrio distribution rights in China and other Asian markets. Management noted uncertainty about the company's ability to continue as a going concern without additional funding or revenue growth.
Altamira Medica AG reported financial results for its Bentrio nasal spray business for the fiscal year 2023. The company generated revenue of CHF 158,213 from product sales, primarily to distributors, while incurring a net loss of CHF 1.78 million. Cost of sales amounted to CHF 225,889, including inventory write-downs of CHF 54,393.Research and development expenses totaled CHF 1.43 million, mainly for completing the clinical trial of Bentrio in seasonal allergic rhinitis in Australia. The company received CHF 134,075 in R&D tax incentives from the Australian government. Selling, general and administrative expenses were CHF 372,479, including costs charged by related party Auris Medical AG.As of December 31, 2023, Altamira had cash and cash equivalents of CHF 490,388 and inventories of CHF 331,061. The company recognized deferred income of CHF 932,200 from an upfront payment related to its licensing agreement with Nuance Pharma for Bentrio distribution rights in China and other Asian markets. Management noted uncertainty about the company's ability to continue as a going concern without additional funding or revenue growth.
生物製藥公司Altamira Therapeutics報告了截至2023年12月31日財政年度的年度財務業績。該公司營業收入爲158,213美元，主要來自對抗空氣過敏原鼻噴藥Bentrio®的銷售。然而，經過考慮銷售成本，該公司錄得了67,676美元的毛虧損，銷售成本總計爲225,889美元。營業虧損達到了1,731,453美元，研發費用對此做出了重要貢獻，爲1,425,373美元。銷售、普通和行政費用報告爲372,479美元。該公司所有者的淨虧損爲1,779,505美元，考慮到外幣翻譯差異後的總綜合虧損爲1,640,922美元。該公司的業務拓展工作包括在澳洲完成Bentrio®的臨床試驗，以...展開全部
生物製藥公司Altamira Therapeutics報告了截至2023年12月31日財政年度的年度財務業績。該公司營業收入爲158,213美元，主要來自對抗空氣過敏原鼻噴藥Bentrio®的銷售。然而，經過考慮銷售成本，該公司錄得了67,676美元的毛虧損，銷售成本總計爲225,889美元。營業虧損達到了1,731,453美元，研發費用對此做出了重要貢獻，爲1,425,373美元。銷售、普通和行政費用報告爲372,479美元。該公司所有者的淨虧損爲1,779,505美元，考慮到外幣翻譯差異後的總綜合虧損爲1,640,922美元。該公司的業務拓展工作包括在澳洲完成Bentrio®的臨床試驗，以及在包括德國在內的某些市場上推出該產品。Altamira Therapeutics還與Nuance Pharma在中國大陸、香港、澳門和韓國簽訂了Bentrio®的獨家許可和分銷協議，其中包括一筆100萬美元的前期付款。展望未來，Altamira Therapeutics計劃繼續努力增加產品收入，產生額外的許可收入，如有必要，籌集進一步的資金以維持足夠的現金儲備。該公司未來的盈利預計將取決於產品市場接受度、監管批准以及其他分銷或許可協議的完成。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間